Literature DB >> 27325860

Is Stereotactic Body Radiotherapy Better Than Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma?

Jen-Fu Yang1, Cheng-Hsiang Lo1, Wen-Yen Huang2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27325860      PMCID： PMC5019752          DOI： 10.1200/JCO.2016.66.4458

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization.

Authors:  Roopinder Gillmore; Sam Stuart; Amy Kirkwood; Ayshea Hameeduddin; Nick Woodward; Andrew K Burroughs; Tim Meyer
Journal:  J Hepatol       Date:  2011-04-15       Impact factor: 25.083

3.  Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.

Authors:  Wen-Yen Huang; Yee-Min Jen; Meei-Shyuan Lee; Li-Ping Chang; Chang-Ming Chen; Kai-Hsiung Ko; Kuen-Tze Lin; Jang-Chun Lin; Hsing-Lung Chao; Chun-Shu Lin; Yu-Fu Su; Chao-Yueh Fan; Yao-Wen Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-17       Impact factor: 7.038

4.  Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma.

Authors:  Alexis Bujold; Christine A Massey; John J Kim; James Brierley; Charles Cho; Rebecca K S Wong; Rob E Dinniwell; Zahra Kassam; Jolie Ringash; Bernard Cummings; Jenna Sykes; Morris Sherman; Jennifer J Knox; Laura A Dawson
Journal:  J Clin Oncol       Date:  2013-04-01       Impact factor: 44.544

5.  Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.

Authors:  Daniel R Wahl; Matthew H Stenmark; Yebin Tao; Erqi L Pollom; Elaine M Caoili; Theodore S Lawrence; Matthew J Schipper; Mary Feng
Journal:  J Clin Oncol       Date:  2015-11-30       Impact factor: 44.544

6.  Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.

Authors:  Ahsun Riaz; Frank H Miller; Laura M Kulik; Paul Nikolaidis; Vahid Yaghmai; Robert J Lewandowski; Mary F Mulcahy; Robert K Ryu; Kent T Sato; Ramona Gupta; Ed Wang; Talia Baker; Michael Abecassis; Al B Benson; Albert A Nemcek; Reed Omary; Riad Salem
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

7.  Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.

Authors:  Julien Edeline; Eveline Boucher; Yan Rolland; Elodie Vauléon; Marc Pracht; Christophe Perrin; Catherine Le Roux; Jean-Luc Raoul
Journal:  Cancer       Date:  2011-06-28       Impact factor: 6.860

Review 8.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

9.  Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma.

Authors:  Tracy R Price; Susan M Perkins; Kumar Sandrasegaran; Mark A Henderson; Mary A Maluccio; Jennifer E Zook; A Joseph Tector; Rodrigo M Vianna; Peter A S Johnstone; Higinia R Cardenes
Journal:  Cancer       Date:  2011-10-24       Impact factor: 6.860

10.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.

Authors:  V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 176.079
  10 in total
  3 in total

1.  Magnetic Resonance Imaging Evaluation of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy: Long Term Imaging Follow-Up.

Authors:  Mishal Mendiratta-Lala; William Masch; Prasad R Shankar; Holly E Hartman; Matthew S Davenport; Matthew J Schipper; Chris Maurino; Kyle C Cuneo; Theodore S Lawrence; Dawn Owen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-09-10       Impact factor: 7.038

2.  Reply to Yang et al and De Bari et al.

Authors:  Daniel R Wahl; Yebin Tao; Matthew Schipper; Theodore S Lawrence; Mary Feng
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

3.  Imaging Findings Within the First 12 Months of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy.

Authors:  Mishal Mendiratta-Lala; Everett Gu; Dawn Owen; Kyle C Cuneo; Latifa Bazzi; Theodore S Lawrence; Hero K Hussain; Matthew S Davenport
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-08-24       Impact factor: 7.038
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.